38 results about "Golgi protein" patented technology

The invention provides a sandwich enzyme-linked immuno sorbent assay (ELISA) quantitative detection method of Golgi protein GP73. Two strains of monoclonal antibodies aiming at different epitopes of a GP73 extracellular domain are used as a coated antibody and a detection antibody; and the GP73 content is detected through substrate developing and a standard curve. A sandwich ELISA quantitative detection kit of the GP73 comprises the coated antibody, the detection antibody, sealing solution, washing buffer, a color reagent, stop solution and a standard substance, wherein the coated antibody and the detection antibody are two strains of monoclonal antibodies aiming at different epitopes of the GP73 extracellular domain; and the amino acid sequences of proteins recognized by the monoclonal antibodies are shown as SEQ ID No. 1 and SEQ ID No. 2 respectively. Through the sandwich ELISA quantitative detection method and the sandwich ELISA quantitative detection kit of the GP73, the sensitivity and the specificity for detecting the GP73 are improved, high stability and reproducibility are guaranteed, the operating time is shortened and the cost is reduced.

The invention relates to an antibody against fucosylated protein GP73, a method for preparing the antibody against the fucosylated protein GP73, a reagent for diagnosing liver cancers, a kit for diagnosing the liver cancers, application of the reagent and / or the kit to preparing products for diagnosing liver diseases and a method for preparing purified fucosylated protein GP73. Occurrence, development and metastasis of liver cancers are diagnosed by detecting the fucosylated protein GP73 or the antibody. The antibody against the fucosylated protein GP73 can be more widely used for affinity chromatography, cDNA library screening, immunologic diagnosis or pharmaceutical preparation.

The invention relates to a novel pneumonosis serum marker, namely a Golgi protein gp73, which belongs to the biological monitoring technical field. The invention also discloses an application of the serum Golgi protein gp73 in diagnosing pneumonosis and provides a detection kit for the serum gp73.

The invention relates to an anti-Golgi protein antibody and an application thereof. The invention recombines human GP73 protein immunity animal to obtain an anti-GP73 polyclonal antibody and a monoclonal antibody which specifically aims at GP73 and builds a plurality of methods for detecting GP73 in clinical tissue sections and serum samples, such as immunohistochemical stain and double antibody sandwiched ELISA method and the like. Tests prove that the polyclonal and monoclonal antibodies can be used for preparing a plurality of GP73 detecting agents of different detecting methods.

The invention discloses a prepack eccentric column of fucosido-fucosyl Golgi protein 73 (or Golgi protein 73 heterogeneous body) relative to liver cancer separation, which is characterized by the following: comprising upper separator tube and lower collecting pipe; packing affinity agent of coupling small lentils agglutinine (LCA); assembling a filter cloth on the bottom of the upper separator tube; packing buffer solution in lower collecting pipe; binding small lentils agglutinine (LCA) and sugar chain fucosido-fucosyl Golgi protein 73; centrifuging through adding into eluent; proceeding purify Fuc-GP73 part. This invention discloses a chemoluminescence testing agent case with the eccentric column and enzyme joint immunoassay agent case with the column and preparing and using method. This agent case can test the content of liver cancer fucosido-fucosyl Golgi protein 73, which can provide support for early stage diagnosis.

The invention relates to the field of diagnosis and treatment of liver cirrhosis and liver fibrosis, in particular to application of Golgi protein 73(GP73) and matter for detecting the concentration of the Golgi protein 73(GP73) in preparation of products for screening or auxiliarily diagnosing liver cirrhosis or liver fibrosis related diseases or products for auxiliarily judging prognosis of the diseases. It is proved that the Golgi protein 73(GP73) can serve as a novel liver cirrhosis marker, also has diagnosis value on liver cirrhosis caused by non-b hepatitis virus infection, and has no diagnosis value on primary liver cancer.

The invention provides a protein micro-array kit for early diagnosis of liver caner as well as a preparation method and an application thereof. The kit can be used for monitoring of development level of chronic hepatitis and prognosis, as well as early diagnosis of the liver cancer. The kit can be used for monitoring expression levels of alpha-fetoprotein, alpha-fetoprotein variant, Golgi protein GP73 and Golgi protein GP73 variants, and determining the prognosis level of a patient and the probability of causing cirrhosis and the liver cancer, thereby providing a direct support for the prevention, diagnosis and treatment of the liver cancer and the hepatitis.

Preferred aspects of the present invention relate to the inhibition of intracellular protein trafficking pathways through selective pharmacologic down-regulation of specific resident ER and golgi proteins, and more particularly, to methods of treating a variety of disease conditions, which depend on these intracellular protein trafficking pathways.

The invention discloses novel phosphorylation sites identified in signal transduction proteins and pathways, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites / proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: adaptor / scaffold proteins, adhesion / extracellular matrix protein, apoptosis proteins, calcium binding proteins, cell cycle regulation proteins, chaperone proteins, chromatin, DNA binding / repair / replication proteins, cytoskeletal proteins, endoplasmic reticulum or golgi proteins, enzyme proteins, G / regulator proteins, inhibitor proteins, motor / contractile proteins, phosphatase, protease, Ser / Thr protein kinases, protein kinase (Tyr)s, receptor / channel / cell surface proteins, RNA binding proteins, transcriptional regulators, tumor suppressor proteins, ubiquitan conjugating system proteins and proteins of unknown function.

The invention discloses a method for detecting Golgi protein 73, a detection reagent and a detection kit used in the method. The detection method comprises the following steps: 1, preparation of a magnetic particle A with an anti GP73 antibody coupled on the surface and preparation of a magnetic particle B with a GP73 antigen coupled on the surface; 2, preparation of a fluorescent-labeled anti GP73 antibody; and 3, detection of GP73 content , to be more specific, a plasma or serum sample is reacted with the magnetic particle A, after the reaction, GP73 is eluted, the fluorescent-labeled anti GP73 antibody is added for incubation, then the magnetic particle B is added to continue incubation, magnetic separation is performed, sample fluorescence value is detected by a fluorescence spectrophotometer, and the GP73 content in the sample is calculated.

The invention relates to a latex-enhanced immunoturbidimetry detection kit of Golgi protein gp73 and a preparation method thereof, and provides latex microspheres coupled with gp73 antibody. The preparation method comprises the following steps: (a) catalyzing N-hydroxysuccinimide to react with carboxyl of carboxyl polystyrene latex microspheres with the particle size being 90-110nm by utilizing DCC, reacting for 8-12 minutes at the temperature of 24-26 DEG C, and carrying out centrifugal treatment to remove supernatant; and (b) taking gp73 antibody solution, precooling to not more than 4 DEG C, adding the gp73 antibody solution into activated carboxyl polystyrene latex microspheres prepared in the step (a), carrying out ultrasonic treatment for 4-6 minutes at 110-130W, and reacting for 25-35 minutes under the temperature of 3-5 DEG C. The invention also provides a kit containing the latex microspheres. The latex microspheres coupled with gp73 antibodies is used for detecting the content of the gp73 protein in a sample, is high in linearity range, high in sensitivity, precision and accuracy, good in repeatability and simple in operation, and can be used for diagnosis of related diseases on clinic.

The invention discloses novel phosphorylation sites identified in signal transduction proteins and pathways, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites / proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: adaptor / scaffold proteins, adhesion / extracellular matrix protein, apoptosis proteins, calcium binding proteins, cell cycle regulation proteins, chaperone proteins, chromatin, DNA binding / repair / replication proteins, cytoskeletal proteins, endoplasmic reticulum or golgi proteins, enzyme proteins, G / regulator proteins, inhibitor proteins, motor / contractile proteins, phosphatase, protease, Ser / Thr protein kinases, Protein kinase (Tyr)s, receptor / channel / cell suface proteins, RNA binding proteins, transcriptional regulators, tumor suppressor proteins, ubiquitan conjugating system proteins and proteins of unknown function.

The invention relates to a magnetic micro-particle chemiluminiscence detection kit for determining the content of Golgi body protein of a human body. The kit comprises a Golgi body protein R1 reagent,a Golgi body protein R2 reagent, a magnetic separation reagent, a calibrator solution series and a chemiluminiscence substrate solution, wherein the Golgi body protein R1 reagent is an anti-Golgi body protein mouse monoclonal antibody diluent marked by fluorescein isothiocyanate, the Golgi body protein R2 reagent is an alkaline phosphatase marked Golgi body protein polyclonal antibody diluent, the magnetic separation reagent is a magnetic micro-particle diluent coated by an anti-fluorescein isothiocyanate mouse monoclonal antibody, the Golgi body protein calibrator solution is composed of a synthesized Golgi body protein antigen and a buffer solution, and the luminescent substrate solution is a Tris-HCl buffer solution which is catalyzed by alkaline phosphatase and contains dioxacycloethane. According to the invention, the signal intensity and sensitivity of immune response are greatly improved, and a more accurate, accurate, convenient, rapid and simple method is provided for the detection of the Golgi body protein.

The invention relates to a kit for determination of human GP73 (Golgi Protein 73) content with a latex-enhanced immunoturbidimetry. The kit comprises a GP73 R1 reagent, a GP73 R2 reagent and a GP73 calibrator, wherein the GP73 R1 reagent comprises an electrolyte, a coagulant, a stabilizer, a surfactant, a preservative and a buffer solution; the GP73 R2 reagent comprises human GP73 resistant polyclonal antibody coated latex particles, an electrolyte, a stabilizer, a surfactant, a preservative and a buffer solution; the GP73 calibrator comprises a preservative, an electrolyte, a stabilizer, a GP73 antigen and a buffer solution. The kit is high in specificity, high in sensitivity, uniform, stable, rapid, convenient and applicable to various biochemical analyzers.

The invention discloses a kit for detecting Golgi protein 73 by a magnetic particle chemiluminescence method and a preparation method thereof, and belongs to the technical field of immunoassay. The kit comprises a streptavidin-coated magnetic particle suspension solution, a biotinylation labeled GP73 antibody solution, an alkaline phosphatase labeled Golgi protein 73 antibody solution, a calibrator, a washing solution and a substrate solution. The problems that pathological specimens need to be obtained in histological detection, the GP73 state of a patient who does not obtain cancer tissue pathology cannot be judged, and repeated detection is difficult are solved. Serological detection has the characteristics of convenience, repeatable measurement, quantification, objectivity, real-time detection and the like. The method has the advantages that the reaction time is short, radioactive contamination is avoided, the experimental operation process is simplified, the binding between the biotin and the streptavidin has extremely high affinity, and the reaction has high specificity. Therefore, non-specific interference is not increased while the sensitivity is improved.

The invention provides a GP73 antigen silicon-based magnetic bead conjugate as well as a competition method GP73 quantitative determination kit formed by taking the conjugate as one of the components and matching with other components. The kit disclosed by the invention consists of a Golgi protein 73 (GP73) antigen silicon-based magnetic bead conjugate working solution, a Golgi protein 73 (GP73) calibration material, an alkaline phosphatase labeled Golgi protein 73 (GP73) monoclonal antibody working solution, a cleaning solution and a chemiluminescence substrate. Meanwhile, the invention provides a method for preparing the GP73 antigen silicon-based magnetic bead conjugate and a method for preparing each component in the kit. The method comprises the following steps: preparing the GP73 antigen silicon-based magnetic bead conjugate working solution, preparing an enzyme-labeled antibody, preparing the calibration material, preparing the cleaning solution and preparing the chemiluminescence substrate. The kit provided by the invention can be mainly applied to diagnosis of primary hepatic carcinoma and has the advantages of high sensitivity, wide linear range, hook effect avoidance, low cost, short detection time consumption and the like.

The invention relates to use of serum markers containing alpha fetal protein (AFP), Golgi protein 73 (GP73) and carcinoembryonic antigen associated cell adhesion molecule 1 (CEACAM1) in diagnosis of liver diseases. Specifically, the invention provides use of reagents containing an associative part of at least one specific binding AFP, an associative part of at least one specific binding GP73 and an associative part of at least one specific binding CECAM1 protein in preparation of kits for diagnosis and / or prognosis of the liver diseases.

The invention discloses novel phosphorylation sites identified in signal transduction proteins and pathways, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites / proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: adaptor / scaffold proteins, adhesion / extracellular matrix protein, apoptosis proteins, calcium binding proteins, cell cycle regulation proteins, chaperone proteins, chromatin, DNA binding / repair / replication proteins, cytoskeletal proteins, endoplasmic reticulum or golgi proteins, enzyme proteins, G / regulator proteins, inhibitor proteins, motor / contractile proteins, phosphatase, protease, Ser / Thr protein kinases, Protein kinase (Tyr)s, receptor / channel / cell surface proteins, RNA binding proteins, transcriptional regulators, tumor suppressor proteins, ubiquitan conjugating system proteins and proteins of unknown function.

The invention relates to the field of diagnosis and treatment of liver cirrhosis and liver fibrosis, in particular to a Golgi protein 73 (GP73) and application of substances for detecting the concentration of the Golgi protein 73 (GP73) to preparation of a product for screening or assisting diagnosis of liver cirrhosis-related or liver fibrosis-related diseases or a product for assisting determination of the prognosis of the diseases. It is proved that the Golgi protein 73 (GP73) can be used as a novel marker of liver cirrhosis, has diagnostic value especially for liver cirrhosis caused by non-hepatitis B virus infection, and has no diagnostic value for primary liver cancer.

The invention discloses a determination kit for Golgi protein 73 and a chemiluminiscence determination method of the Golgi protein 73, and relates to the technical field of biology. Thedetection kit comprises a magnetic particle reagent, a GP73 binding antibody and a GP73 labeling antibody, combines a magnetic particle technology with an acridinium ester labeling technology, effectively shortens the detection time of Golgi protein 73, and is high in detection sensitivity, strong in specificity and good in stability.

The invention relates to a Golgi apparatus protein 73 monoclonal antibody, a kit containing the antibody and application of the Golgi apparatus protein 73 monoclonal antibody in detection of Golgi apparatus protein 73. The invention also relates to a method for detecting the level of Golgi apparatus protein 73 in serum. The kit containing the GP73 monoclonal antibody is used for detecting GP73 inhuman serum, and has high sensitivity and strong specificity. Moreover, the kit and the method provided by the invention can be clinically used for auxiliary diagnosis of liver cirrhosis.

The invention relates to the field of biological detection, in particular to a detection kit for quantitatively detecting AFP (Alpha Fetal Protein), Golgi Protein-73GP73 and PIVKA (Protein Induced Vy Vitamin K Absence)-II or an antagonist-II as well as a preparation method and application of the detection kit. The detection kit comprises an AFP detection test paper card, a Golgi Protein-73GP73 detection test paper card and a PIVKA-II detection test paper card which are independent of one another, wherein each detection test paper card comprises a bottom plate, a sample pad, a gold-labeled pad, a nitrocellulose membrane and a water absorbing pad, wherein the sample pad, the gold-labeled pad, the nitrocellulose membrane and the water absorbing pad are positioned on the surface of the bottom plate and are arranged from the sample adding end in sequence. The kit provided by the invention has the benefits that the AFP, the GP73 and the PIVKA-II are firstly detected through a fluorescent microsphere immune chromatography, and both the sensitivity and the specificity are realized; the kit has the advantages of high quickness, simplicity and convenience in operation, accurate results, good economy and applicability and the like.

The present invention discloses a Golgi protein-73 mini-ELISA detection system comprising a kit, a portable fluorescence detector, a magnet plate and a magnetic bead carrier, wherein the kit comprises a sample diluent, a washing buffer, an antibody diluent, a Blocking buffer, a chromogenic reagent, a stop solution, a bead activator, a GP73 standard, Golgi protein-73 recognization monoclonal antibody 5F10 and horse radish peroxidase-labeled Golgi protein-73 recognization monoclonal antibody 5B12. The invention also discloses a using method of the detection system. The Golgi protein-73 mini-ELISA detection system does not require the use of a microplate reader, and can be used in relevant units being lack of large equipment. The system can be used to complete the entire testing process on the basis of an immunomagnetic bead serum GP73 double monoclonal antibody sandwich ELISA test kit by combination of a portable fluorescence detector, testing cost is low, and operation is simple and efficient.

The present invention relates to a method for treating breast cancer in a subject having a breast cancer of the triple-negative type, which method comprises the step of administering to said subject a therapeutically effective amount of a modulator of the protein tyrosine phosphatase, non-receptor type 11 (PTPN11) gene or of its gene product (Shp2). The present invention also relates to a method for treating breast cancer in a subject having a breast cancer over-expressing the “SHP2 signature” genes, as compared to normal breast tissue samples, which method comprises the step of administering to said subject a therapeutically effective amount of a modulator of the protein tyrosine phosphatase, non-receptor type 11 (PTPN11) gene or of its gene product (Shp2), wherein said “SHP2 signature” genes consist of the genes SGCB, ZSCAN12, ID4, ZIC3, CPVL, HLA-A, MCOLN3, SPATA18, TMEM45A, GNAL, CYBRD1, TSPAN7, ZEB1, CNTLN, NEFL, CENPV, ARL6, HPRT1, LRRC34, PDPN, BEND7, SLC16A10, FAM27E1, PLEKHA1, HERC5, CHIC1, PHF6, ELOVL4, ANTXR1, PRAME, SCML1, CLIP4, CECR2, CNOT10, IGF2BP3, NAP1L3, GPC3, KIAA1804, DGKE, FAS, EPHA6, KDELC1, CRISPLD1, DOCK3, ACSL4, CNTNAP3, PLEKHM3, RDX, TBX18, RRAGD, HOXB5, SNCA, FUNDC2, ITGA8, HFM1, IGF2BP2, CCND2, SGTB, MKX, CRYBG3, WBP5, LPHN3, BEX4, CPNE8, GLDC, SLC35F1, HOXA13, SERPINF1, NEFM, SYCP2L, FHL1, APOBEC3C, CALD1, FKBP10, HOXD11, DENND2C, LRRC49, FAM55C, KIAA0408, HOXB9, C160RF62, ACN9, TUSC3, ELOVL2, SPOCK3, HOXB6, WDR35, MPP1, FBX038, PRKAA2, SLAIN1, NPHP3, KIAA1524, PRPS1, GJC1, AMOT, SLC9A6, KCTD12, NUP62CL, DZIP3, JAM3, HOXA9, ANKRD19, CDKN2A, BCAT1, OAT, LPHN2, CCDC82, HSD17B11, SAMHD1, WDR17, STK33, GSTP1, TRPC1, CKB, LIN28B, ALDH1L2, SACS, CLGN, MY03A, EPB41L3, SLC25A27, VCAN, GPX8, GALNT13, PVRL3, MOXD1, HEY1, MAP7D3, ESD, MPP6, EYA4, SPG20, ZDBF2, ZNF204, IFT57, AKR1B1, ADAT2, ZNF717, CCDC88A, ZNF215, MIDI, FBN2, LOC100130876, TCEAL8, IGF2BP1, ANKRD18B, PLAGL1, PM20D2, LDHB, C150RF51, PTPN11, EPB41L2, TLE4, GOLM1, C60RF192, HOXD13, SLIT2, UCHL1, DYNC2H1, CPS1, GPR180, PYGL, NRN1, PRTFDC1, SLC16A1, DSC3, TMC01, LRCH2, SLC6A15, DZIP1, HOXA5, HSPA4L, CDR1, PLS3, ECHDC1, SMARCA1, CXORF57, HOXD10, and IRS4.

The invention provides a method for detecting Golgi protein 73 (GP73) by using an electrochemical / colorimetric dual-mode sensor based on H-rGO-Mn3O4 nano-enzyme, which comprises the following steps: modifying a screen-printed electrode by using gold nanoparticles (Au NPs), and fixing a complementary chain (cDNA) of a GP73 aptamer (Apt) on the surface of the electrode; the Apt is fixed on the surface of the H-rGO-Mn3O4 nano enzyme to serve as a detection probe; the electrochemical / colorimetric dual-mode aptamer sensor based on the H-rGO-Mn3O4 nano-enzyme is constructed by utilizing the competitive effect between cDNA and a detection probe and between GP73 and the detection probe, adopting 3, 3 ', 5, 5'-tetramethyl benzidine (TMB) as an electrochemical and colorimetric dual-function probe and utilizing a nano-enzyme catalytic signal amplification mode, dual-signal detection of GP73 is realized, and the lowest detection limit is 0.1 pg / mL.

The invention relates to a kit for detecting Golgi protein 73 (GP73) mRNA (messenger Ribonucleic Acid) by real-time fluorescent quantitative PCR (Polymerase Chain Reaction), cDNA (complementary Deoxyribonucleic Acid) is obtained by reverse transcription (RT) of an mRNA sample, and the mRNA expression quantity of a specimen GP73 can be quantitatively detected by combining a real-time fluorescent quantitative PCR detection technology. The kit provided by the invention can be used for detecting the expression of GP73 in peripheral blood of a patient in clinic and scientific research, and providesan important reference basis for determination and prognosis judgment of primary liver cancer (PHC).

Disclosed herein are antibodies and methods of using said antibodies to detect Golgi protein 73 (GP73) and fucosylated GP73 in a sample.

The invention relates to the field of biological detection, and particularly relates to a detection kit for quantitatively detecting alpha fetoprotein (AFP) and Golgi protein-73 (GP-73), a preparation method and application thereof. The kit comprises an AFP detection test paper card and a GP-73 detection test paper card which are independent from each other, wherein each detection test paper card comprises a bottom plate, as well as a sample pad, a gold mark pad, a nitrocellulose film and a water absorption pad which are arranged on the surface of the bottom plate and are sequentially arranged from a feeding end. The kit detects AFP and GP73 by using a fluorescent microspherev immunochromatography technology for the first time, has sensitivity and specificity, has the advantages of quick and simple operation, accurate result and the like, and is economical and practical.

The invention relates to the field of diagnosis and treatment of liver cirrhosis and liver fibrosis. The invention specifically relates to Golgi protein 73 (GP73) and substances used to detect the concentration of Golgi protein 73 (GP73) in the preparation of screening or auxiliary diagnosis of liver cirrhosis or Applications in products for liver fibrosis-related diseases or products that assist in judging the prognosis of diseases. The invention proves that Golgi body protein 73 (GP73) can be used as a new marker of liver cirrhosis, and especially has diagnostic value for liver cirrhosis caused by non-hepatitis B virus infection, but has no diagnostic value for primary liver cancer.